<DOC>
	<DOCNO>NCT02864849</DOCNO>
	<brief_summary>This study design test efficacy safety total neoadjuvant induction consolidation CapeOX plus neoadjuvant intensity modulate radiotherapy concurrent capecitabine MRI define high-risk rectal cancer .</brief_summary>
	<brief_title>Total Neoadjuvant Induction Consolidation CapeOX Plus IMRT With Capecitabine MRI Defined High-risk Rectal Cancer</brief_title>
	<detailed_description>This phase II trial study efficacy safety total neoadjuvant treatment MRI define high-risk locally advanced rectal cancer . MRI image feature mrT3c/T3d/T4a/T4b , threaten circumferential resection margin , mrN2 disease extramural vascular invasion define high-risk factor prove associate unfavorable oncological outcome , especially distant metastasis . Induction consolidation chemotherapy plus radiation may increase systemic local control . Total neoadjuvant treatment schedule also advantage improved patient tolerance , early closure defunctioning ileostomy etc . In study , patient MRI define high-risk rectal cancer receive 3 cycle induction CapeOX , intensity modulate radiotherapy concurrent capecitabine 2 cycle consolidation CapeOX Total mesorectal excision . The induction chemotherapy relate G3-4 toxicity occur 42 % patient GCR-3 trial ( 23 % RT , 19 % induction chemotherapy ) . It hypothesize neoadjuvant chemotherapy relate G3-4 toxicity rate present regimen low 25 % ( 10 % IMRT , 15 % induction/consolidation chemotherapy ) . A sample size 67 achieve 80 % power detect difference ( △P =17 % , P1=25 % , P0=42 % ) use one-sided binomial test . ( α= 0.05 ) . If number G3-4 toxic event 21 less , hypothesis P1 &gt; = 42 % reject . About 10 % loss follow-up anticipate , additional eight patient recruit . The study require 75 subject .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Age ≥ 18 year ≤75 year . ECOG Performance status 01 . Histologically confirm diagnosis adenocarcinoma rectum . The distance verge tumor analrectal junction ( ARJ ) ≤8cm base MRI , ≤12 cm base sigmoidoscopy . Clinical Stage T3c , T3d , T4a T4b , EMVI ( + ) mrN2 CRM ( + ) base MRI . No evidence distant metastasis . No prior pelvic radiation therapy . No prior chemotherapy surgery rectal cancer . No active infection require systemic antibiotic treatment . ANC &gt; 1.5 cells/mm3 , HGB &gt; 10.0 g/dL , PLT &gt; 100,000/mm3 , total bilirubin ≤ 1.5 x ULN , AST≤ 3 x ULN , ALT ≤ 3 x ULN . Patients must read , agree , sign statement Informed Consent prior participation study . Recurrent rectal cancer . Anticipated unresectable tumor neoadjuvant treatment . Creatinine level great 1.5 time upper limit normal . Patients receive prior pelvic radiotherapy . Patients unable undergo MRI . Patients history prior malignancy within past 5 year , except adequately treat basal cell squamous cell skin cancer . Patients history arterial thrombotic event within past 6 month . This include angina ( stable unstable ) , MI , TIA , CVA . Other Anticancer Experimental Therapy . Women pregnant breastfeeding . Patients concurrent medical psychiatric condition disease would make inappropriate candidate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Rectal cancer</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>toxicity</keyword>
</DOC>